Ertugliflozin - Merck/Pfizer

Drug Profile

Ertugliflozin - Merck/Pfizer

Alternative Names: MK-8835; PF-04971729; PF-4971729; STEGLATRO

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Type 2 diabetes mellitus
  • Discontinued Hypertension

Most Recent Events

  • 31 Jan 2018 Merck Sharp & Dohme Corp. plans the ERADICATE-HF phase II trial for Type 2 diabetes mellitus and Heart failure in March 201(NCT03416270)
  • 25 Jan 2018 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of ertugliflozin for Type-2 diabetes mellitus in European Union
  • 22 Dec 2017 Merck completes the phase III VERTIS trial in Type-2 diabetes mellitus (Adjunctive therapy) in South Korea (PO) (NCT02630706)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top